Diferencia entre revisiones de «Dobutamine»
Sin resumen de edición |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestran 17 ediciones intermedias de 10 usuarios) | |||
| Línea 1: | Línea 1: | ||
==General== | ==General== | ||
*Type: [[Vasopressors]] | *Type: [[Is DrugClass::Vasopressors]] | ||
**Technically an inotrope as beta 2 stimulation causes vasodilation | |||
**Should use in combination with a [[Vasopressors|vasopressor]] (eg [[norepinephrine]]) to avoid hypotension | |||
*Dosage Forms: | *Dosage Forms: | ||
*Common Trade Names: | *Common Trade Names: | ||
| Línea 15: | Línea 17: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: | ||
** Unknown if Dobutamine passes into breast milk | |||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
*** Not defined | |||
**Pediatric | **Pediatric | ||
*** Not defined | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
*** Not defined | |||
**Pediatric | **Pediatric | ||
*** Not defined | |||
==Contraindications== | ==Contraindications== | ||
| Línea 30: | Línea 37: | ||
*Tachyarrhythmias | *Tachyarrhythmias | ||
*Myocardial ischemia | *Myocardial ischemia | ||
*[[Hypotension]]as | *[[Hypotension]] as β<sub>2</sub> effect may result in vasodilation | ||
**Caution if SBP <90 | **Caution if SBP <90 | ||
| Línea 37: | Línea 44: | ||
===Common=== | ===Common=== | ||
==Pharmacology== | ==Pharmacology<ref>Dobutamine: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019. </ref>== | ||
*Half-life: | *Half-life: | ||
** 2 minutes | |||
*Metabolism: | *Metabolism: | ||
** In tissues and hepatically | |||
*Excretion: | *Excretion: | ||
*Mechanism of Action: | ** Urine as metabolites | ||
*Mechanism of Action:β<sub>1</sub> stimulation with variable BP effects | |||
===Primary Receptor=== | ===Primary Receptor=== | ||
* | *β<sub>1</sub> | ||
* | *β<sub>2</sub> | ||
===Relative Effects=== | ===Relative Effects=== | ||
*↑↑↑SV | *↑↑↑SV | ||
*↑↑HR | *↑↑HR → increases oxygen demand of heart → can worsen ischemia | ||
*↓SVR (transient, from | *↓SVR (transient, from β<sub>2</sub> agonism) | ||
==Notes== | ==Notes== | ||
===Indications=== | ===Indications=== | ||
*Cardiogenic shock | *Cardiogenic shock | ||
* | **initial agent in low-output heart failure without requiring BP support | ||
*Tricyclic overdose | *Tricyclic overdose | ||
*septic shock with low cardiac output to improve blood flow | |||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Dobutamine]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
http://www.atsjournals.org/doi/abs/10.1164/rccm.201006-0972CI?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed#readcube-epdf | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Critical Care]] | ||
Revisión actual - 21:55 20 mar 2026
General
- Type: Vasopressors
- Technically an inotrope as beta 2 stimulation causes vasodilation
- Should use in combination with a vasopressor (eg norepinephrine) to avoid hypotension
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Dosing
- 2-20mcg/kg/min
- 10mcg works for most
- May use in peripheral IV
Rate of Titration
- Q2-5 min
Pediatric Dosing
Special Populations
- Pregnancy Rating: B
- Lactation:
- Unknown if Dobutamine passes into breast milk
- Renal Dosing
- Adult
- Not defined
- Pediatric
- Not defined
- Adult
- Hepatic Dosing
- Adult
- Not defined
- Pediatric
- Not defined
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
- Tachyarrhythmias
- Myocardial ischemia
- Hypotension as β2 effect may result in vasodilation
- Caution if SBP <90
Serious
Common
Pharmacology[1]
- Half-life:
- 2 minutes
- Metabolism:
- In tissues and hepatically
- Excretion:
- Urine as metabolites
- Mechanism of Action:β1 stimulation with variable BP effects
Primary Receptor
- β1
- β2
Relative Effects
- ↑↑↑SV
- ↑↑HR → increases oxygen demand of heart → can worsen ischemia
- ↓SVR (transient, from β2 agonism)
Notes
Indications
- Cardiogenic shock
- initial agent in low-output heart failure without requiring BP support
- Tricyclic overdose
- septic shock with low cardiac output to improve blood flow
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Coarctation of the aorta | 5-10mcg/kg/min IV | Inotropic support for CHF | IV | Pediatric |
| Congestive heart failure | 2-20 mcg/kg/min IV drip | Inotrope (1st line for hypotensive HF) | IV drip | Adult |
| Sepsis (main) | 2-20 mcg/kg/min | Inotrope for sepsis-related myocardial dysfunction | IV drip | Adult |
| Vasopressors | 2-5 mcg/kg/min, max 20 mcg/kg/min | Inotrope | IV drip | Adult |
| Vasopressors | 2-20mcg/kg/min | Inotrope for cardiogenic shock | IV | Adult |
See Also
References
- ↑ Dobutamine: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.